145 results about "Tumor reduction" patented technology

The invention belongs to the technical field of medicines, and particularly relates to quinazoline stilbene derivatives as well as a preparation method, a composition and application thereof. The quinazoline stilbene derivative is synthesized by combining quinazoline with pharmacophores such as a styrene skeleton, and the quinazoline stilbene derivative structurally contains functional units such as a quinazoline functional unit and the pharmacophores such as the styrene skeleton, so that the compound is endowed with good anti-tumor activity. Researches show that the quinazoline stilbene derivative has a good anti-tumor effect including KRASG12C mutation non-small cell lung cancer, has the advantage of multi-target action, has an adjusting effect on Src kinase and related downstream signal channels of Statat, mTOR, Akt and PI3k, and is beneficial to reduction of tumor drug resistance. Compared with a complex structure modified compound, the quinazoline stilbene derivative disclosed by the invention is simple in structure and easy to prepare, and has a good application prospect.

The invention discloses a compound with anti-tumor activity. The compound has a chemical structural formula as shown in a formula (I). The compound belongs to a novel tetracyclic triterpenoid natural product, has good fat solubility and chemical stability, and can be conveniently extracted from the rhizome of a herbal medicine Polygala fallax Hemsl. And prepared into an oral or injection form. The invention also provides a preparation method and application of the compound. The compound provided by the invention can obviously inhibit the growth of mouse lung cancer and reduce the volume and weight of tumor, and can be used for treating tumor diseases.

Methods for treating cancers and precancerous conditions by administering an effective amount of a radiolabeled agent that targets cell surface phosphatidylserine, alone or in combination with other therapies, are provided. The radiolabeled phosphatidylserine targeting agent delivers radiation to cells that externally present phosphatidylserine, such as tumor cells, depleting those cells and neighboring malignant cells to effect overall tumor reduction. Radiation delivered by the radiolabeled phosphatidylserine targeting agent itself increases the cell surface expression of phosphatidylserine, leading to a feed-forward mechanism that drives further accumulation of the phosphatidylserine targeting agent at target lesions to enhance its therapeutic effect.

The invention provides an application of clofazimine in preparation of a medicine for treating cancers. Animal experiments show that clofazimine can regulate the tumor immune environment and enhance the anti-tumor immune effect; the number of tumors is reduced, and tumor bodies are reduced; the survival time of tumor animals is prolonged.

In some aspects, the present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising administering a KRAS inhibitor and a regulatory T cell (Treg)-depleting agent to the subject. In some aspects, the present disclosure is further directed to methods of reducing the number of Treg cells (Tregs) in a tumor environment (TME) in a subject who receives a therapy with a KRAS inhibitor comprising administering a Treg-depleting agent to the subject. In some aspects, the present disclosure is further directed to methods of treating a tumor in a subject who is identified as having an increased number of Tregs in a TME, or as having a spatial cellular community comprising Tregs in a TME.

The invention relates to application of indole-3-propionic acid in preparation of drugs for preventing and treating pulmonary ischemia reperfusion injury. Through in-vivo animals, the inventor finds that indole-3-propionic acid can reduce the lung injury score in a concentration-dependent manner, reduce the wet weight / dry weight ratio of lungs, relieve active oxygen accumulation after lung ischemia reperfusion, and reduce the levels of total protein, tumor necrosis factor alpha and interleukin 6 in alveolar lavage fluid; the cell level also shows that the indole-3-propionic acid can improve the vitality of alveolar epithelial cells after ischemia / reperfusion injury simulation in a concentration-dependent manner, reduce release of inflammatory factors such as tumor necrosis factors alpha, interleukin 6 and interleukin 1beta, and reduce accumulation of active oxygen in the cells. Results of integrating in-vitro cells and in-vivo animals show that the indole-3-propionic acid has the effect of preventing and treating the pulmonary ischemia reperfusion injury and has a good clinical application prospect.

Provided herein are compositions of NK-92™ cells that express a combination of PD-L1 CAR, CD16 and IL2, and the method of using these cells to to reduce tumor cells and cells in tumor microenvironment (e.g., MDSCs or TAMs) and treat cancer.

The invention provides a bionic MOF nano platform capable of double targeting cervical cancer tumor cells and cancer-related fibroblasts and co-delivering an FAK inhibitor and bismuth as well as a preparation method and application thereof, the bionic MOF nano platform comprises an MOF material loaded with the FAK inhibitor (IN10018) and bismuth (Bi), and a hybrid membrane coating the outer part of the MOF material loaded with the FAK inhibitor and the bismuth, the hybrid membrane is obtained by mixing and physically extruding a cervical cancer tumor cell (HeLa and SiHa) membrane and a cancer-related fibroblast (CAFs) membrane. According to the bionic MOF nano platform, in an acid environment, the ZIF-8 nano particles loaded with the IN10018 and the Bi disintegrate, the IN10018 is released, CAFs infiltration in tumors is reduced, meanwhile, due to addition of the Bi, the radiation absorption efficiency is improved, and the sensitivity of the tumors to radiotherapy is further enhanced through a double-targeting mechanism.

Provided herein are compositions of NK-92™ cells that express a combination of PD-L1 CAR, CD16 and IL2, and the method of using these cells to to reduce tumor cells and cells in tumor microenvironment (e.g., MDSCs or TAMs) and treat cancer.

The present invention provides a biomimetic MOF nanoplatform that can dual-target cervical cancer tumor cells and cancer-associated fibroblasts and co-deliver FAK inhibitors and bismuth, and its preparation method and application. The biomimetic MOF nanoplatform includes a MOF material loaded with FAK inhibitors (IN10018) and bismuth (Bi), and a hybrid membrane coated on the outside of the MOF material loaded with FAK inhibitors and bismuth. The hybrid membrane is obtained by physical extrusion after mixing cervical cancer tumor cell (HeLa and SiHa) membranes and cancer-associated fibroblast (CAFs) membranes. In an acidic environment, the biomimetic MOF nanoplatform of the present invention disintegrates ZIF-8 nanoparticles loaded with IN10018 and Bi, releases IN10018, reduces CAFs infiltration in the tumor, and at the same time, the addition of Bi improves radiation absorption efficiency, further enhancing the sensitivity of the tumor to radiotherapy through a dual-targeting mechanism.

The invention discloses a manifold confrontation field self-adaption-based tumor diagnosis method, which comprises the following steps of: firstly, pre-training, and using a model pre-trained by source domain data as a model initialization parameter; then, manifold confrontation field self-adaption is carried out, a confrontation learning network framework is designed, a discriminant manifold propagation method is introduced to adjust structural parameters of a manifold module, manifold learning is used for assisting confrontation learning to further minimize the source domain and target domain feature mapping distance, and a target domain feature extractor is trained; and finally, testing, inputting a target domain test tumor image into a feature extractor after adversarial training to extract features, and then classifying data by using a trained classifier to obtain a tumor image classification result. The objective of the invention is to provide a manifold confrontation field-based adaptive tumor diagnosis method, which solves the dependence of existing deep learning on a large amount of labeled data, reduces the sample labeling cost in tumor diagnosis, reduces the labor intensity of doctors and experts, and realizes automatic and high-precision diagnosis classification of non-labeled medical tumor images.

The invention discloses a puncture sampling device for medical oncology, which comprises a sampling body, and the sampling body comprises a needle tube; the needle head is inserted into the pathogen position of a patient, then the piston is pulled, negative pressure is generated in the needle tube when the piston is pulled, tumor tissue at the pathogen position can be adsorbed into the sampling groove formed in the top end of the needle head, and at the moment, a medical worker rotates the pressing handle by pressing the pressing handle; at the moment, along with rotation of a pressing handle, a connecting rod can be driven to move in a cutting outer barrel, and then a connecting shaft is driven to slide and adjust on the inner side of an arc-shaped groove formed in the bottom end of a fixed blade, and along with sliding of the connecting shaft, a rotating blade can be driven to rotate towards one end of the fixed blade through a connecting block; the tumor tissue adsorbed into the sampling groove is cut off, the tumor tissue which is adsorbed into the sampling groove and is in a growth connection state can be cut off and sampled through the cutting-off assembly, and the situation that the tumor falls off from the interior of the needle head after being sampled is reduced.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating lung cancer and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines: lily, radix ophiopogonis, thunberg fritillary bulb, astragalus membranaceus, curcuma zedoary, lychee seed, poria cocos, radix scrophulariae, rhizoma anemarrhenae and loofah sponge. The traditional Chinese medicine composition has the effects of tonifying qi and yin, reducing phlegm and resolving masses, and is particularly suitable for treating a patient suffering from qi-yin deficiency and blood stasis type small cell lung cancer. The traditional Chinese medicine composition disclosed by the invention has the effects of reducing tumor cell proliferation, regulating tumor immunity, reducing toxicity and enhancing efficacy, and can also enhance the immunity of a patient, prolong the lifetime of the patient and improve the living quality of the patient.

In some aspects, the present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising administering a KRAS inhibitor and a regulatory T cell (Treg)-depleting agent to the subject. In some aspects, the present disclosure is further directed to methods of reducing the number of Treg cells (Tregs) in a tumor environment (TME) in a subject who receives a therapy with a KRAS inhibitor comprising administering a Treg-depleting agent to the subject. In some aspects, the present disclosure is further directed to methods of treating a tumor in a subject who is identified as having an increased number of Tregs in a TME, or as having a spatial cellular community comprising Tregs in a TME.

The invention relates to the field of biological medicines, and discloses application of patinopectin-like in preparation of a medicine for relieving and / or treating non-small cell lung cancer. Tests find that on the cellular level, the activity of non-small cell lung cancer cells can be reduced, cell migration can be inhibited, and the cell apoptosis process can be activated through treatment with the patinopectin-like; on the protein expression level, apoptosis-related protein can be remarkably activated, non-small cell lung cancer can be effectively treated by adjusting signal channels such as EGFR / PI3K / AKT, the possibility that tumor cells escape in treatment can be reduced, and therefore the clinical treatment efficiency is improved, and the application prospect is extremely good.

One aspect of the present invention relates to: a conjugate comprising a peptide of a novel sequence and glycyrrhizin; and a pharmaceutical composition for preventing or treating obesity, the composition comprising the conjugate. The conjugate and composition comprising same according to one aspect were found to inhibit hypertrophy of fat cells, increase the cell membrane expression level of ATP-binding cassette transporter A1 (ABCA1), and reduce the secretion of tumor necrosis factor-α (TNF-α). In addition, the conjugate and composition comprising same were found to remain in a greater amount in the blood and have better pharmacokinetic properties than glycyrrhizin used by itself, and thus can be used in the obesity prevention and / or treatment market / industry.

The application belongs to the technical field of medicine, and relates to 3-benzylamino coumarin compounds and application thereof. Experimental results show that the compounds can significantly increase the survival rate of HUVEC cells in a high-sugar environment, and resist blood vessel injury caused by high sugar. The compounds can increase the release amount of NO in HUVEC cells damaged by high sugar, reduce the generation of malondialdehyde, and reduce the generation of tumor necrosis factor alpha.

The present invention provides combination therapies for reducing or preventing tumor progression or treating cancer using a binding agent comprising at least one binding region that binds CD27 in combination with a PD1 / PD-L1 inhibitor.

Disclosed herein are compositions and methods for treating cancer, specifically extensive-stage small-cell lung cancer (ES-SCLC), through the administration of a combination therapy. In some embodiments, the method comprises administering plinabulin, one or more immune checkpoint inhibitors, including but not limited to pembrolizumab, and a regimen of etoposide with a platinum-based agent (EP). The disclosed methods enhance tumor reduction, prolong progression-free survival, and improve overall treatment efficacy compared to traditional therapies.

The present invention belongs to the field of pharmaceutical synthesis, and specifically relates to salviphorol derivatives and their application in drugs for treating cancer cachexia. Salviphorol compounds include compounds represented by formula (X) and / or formula (Y), or pharmaceutically acceptable salts or optical isomers of the compounds represented by formula (X) and / or formula (Y). The present invention also provides a pharmaceutical composition for treating cachexia diseases, and its application in the preparation of drugs for treating cancer cachexia, including muscle atrophy caused by tumor tissues, fat reduction caused by tumor tissues, reduced appetite caused by tumor tissues, inflammatory responses caused by tumor tissues, and cancer cachexia caused by digestive tract-related cancers, liver cancer, lung cancer, and colon cancer. The present invention also provides its application in the preparation of drugs or inhibitors for treating or inhibiting muscle atrophy, drugs or inhibitors for inhibiting or alleviating adipocyte lipolysis, and drugs or inhibitors for inhibiting or alleviating weight loss or reduction.

The invention relates to the technical field of medicines, and discloses a bifidobacterium longum strain GZBAI 01 and application thereof in degradation of benzoic acid and prevention or treatment of colorectal cancer. The strain is separated from faeces of healthy people, genomics identification is carried out, the metabolic profile of the strain is measured through metabonomics, the strain can convert benzoic acid with carcinogenic risk into protocatechuic acid with antitumor activity through unique metabolic capability, meanwhile, the function of regulatory T cells (Treg) in tumor drainage lymph nodes can be inhibited, differentiation of CD8 + T cells is promoted, and the tumor drainage lymph nodes can be inhibited. Therefore, the colorectal cancer is prevented through double ways of eliminating cancerogen and generating therapeutic agents. A colorectal cancer mouse model and a subcutaneous tumor mouse model verify that the strain can significantly reduce the number and volume of tumors, and shows a benzoic acid conversion effect superior to that of other strains in vivo and in vitro, and a new way is provided for prevention and treatment of colorectal cancer.

The invention discloses application of a histone deacetylase inhibitor combined with a CAR-T cell targeting DR5 in preparation of a medicine for treating tumors, and further provides a combined medicine for treating tumors, and the combined medicine comprises the histone deacetylase inhibitor and the CAR-T cell targeting DR5. The CAR-T cells targeting DR5 and the histone deacetylase inhibitor are combined for use, and the CAR-T cells and the histone deacetylase inhibitor can generate a synergistic effect, can generate an excellent curative effect on malignant tumors, and can reduce the dosage of the CAR-T cells, reduce the depletion of the CAR-T cells, reduce the level of cell factors, increase the safety of CAR-T treatment and reduce the treatment cost; moreover, tumor cells are more sensitive to DR5CAR-T, and tumor escape is reduced.

The invention discloses an antigen binding polypeptide combined with CD47 or an antigen binding part and application thereof. Specifically, the invention provides an antigen binding polypeptide binding CD47 and an antigen binding part thereof, nucleic acid encoding the antigen binding polypeptide and the antigen binding part, a carrier containing the nucleic acid, a cell containing the carrier, a pharmaceutical composition containing the antigen binding polypeptide and the antigen binding part, and application of the antigen binding polypeptide and the antigen binding part in reducing tumors or inhibiting growth of tumor cells, treating cancers, promoting phagocytosis of macrophages and the like.

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

The invention belongs to the technical field of biological medicines, and particularly relates to a pharmaceutical composition containing carboxamide triazole or pharmaceutically acceptable salts thereof and application of the pharmaceutical composition in preparation of medicines for preventing or treating fibrosis-related diseases. Specifically, the invention discovers that the carboxylamine triazole orotate (CTO) can directly inhibit fibroblast collagen generation and cross-linking maturation, so that the fibrosis degree is reduced; when the polypeptide is combined with a PD-1 antibody, collagen deposition in tumor tissues can be reduced by inducing normalization of a tumor matrix in a synergistic manner, the tumor permeation concentration of chemotherapeutic drugs is remarkably enhanced, and the anti-tumor curative effect is improved. The invention can be applied to the treatment of various matrix dense solid tumors including pancreatic cancer, breast cancer, colorectal cancer and lung adenocarcinoma, and is expanded for intervention of fibrosis-related diseases, thereby providing a new treatment strategy for improving the efficacy of chemotherapeutic drugs and improving immunotherapy response through targeted matrix remodeling.

The invention relates to the field of biological medicines, in particular to a PD-L1 targeting polypeptide and application thereof. The present invention provides a PD-L1 targeting polypeptide, which is characterized in that the polypeptide comprises a first fragment and a second fragment, the first fragment is used for binding with PD-L1, the second fragment is used for mediating degradation of PD-L1 in lysosome, and the first fragment comprises an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4. The polypeptide provided by the invention can promote the degradation of PD-L1 protein through lysosome, reduce the content of PD-L1 expressed by tumor cells and / or exosomes, fundamentally avoid and reduce the interaction between PD-L1 and PD-1, and have better inhibition effect and treatment effect.

The invention belongs to the technical field of biological medicine, and particularly relates to application of coniferyl aldehyde in preparation of anti-cancer drugs. The invention discloses application of coniferyl aldehyde in preparation of anti-cancer drugs, coniferyl aldehyde can significantly inhibit invasion and migration ability of hepatocellular carcinoma cells, cancer cells cannot break through primary parts through key links such as interference of movement and adhesion of the cancer cells and degradation of extracellular matrixes, invasion of tumors to surrounding tissues is reduced, and the anti-cancer effect is improved. The occurrence rate of remote metastasis is reduced, the non-metastasis lifetime of the patient is prolonged, and more treatment time and survival opportunities are won for the patient; a large number of cell experiments and animal experiments prove that the medicine has no obvious liver and kidney toxicity under the treatment dosage, the tolerance of a patient to treatment is improved, the smooth proceeding of the treatment process is guaranteed, and the living quality of the patient is effectively improved.

The inventors have prepared a novel anti-Cath-D antibody (F1M1) that can reduce tumor growth in a Cath-D secreting basal-like TNBC cell line with strong immune infiltration, without significant toxicity. The F1M1 antibody prevents recruitment of immunosuppressive M2 polarized tumor-associated macrophages (TAMs) and induces activation of natural killer cells in the tumor, and the F1M1 also enhances activation of antitumor M1 polarized TAM, recruitment and maturation of conventional cDC1 dendritic cells in the tumor to promote antigen presentation and reduce depletion marker expression of CD4 + and CD8 + T cells in the tumor and drainage lymph nodes. It is worthy of noting that the affinity of the antibody F1M1 to Cath-D is better than that of the antibody F1 prepared by the inventor in advance. The inventors also have prepared a novel Fc-optimized F1M1-Fc + human antibody which can promote ADCC induction of cancer cells and CAF, improve anti-tumor efficacy, and trigger recruitment, activation and cytotoxic activity of NK cells in tumors. The F1M1-Fc + F1M1-Fc + can inhibit the growth of MDA-MB-231 and SUM159 TNBC cell xenografts and two TNBC-PDX (one of the TNBC-PDX is resistant to neoadjuvant chemotherapy), and has no obvious toxicity. In addition, the F1M1-Fc < + > improves the treatment effect of the paclitaxel and enzalutamide combined medicine. Thus, the present invention relates to anti-cathepsin-D antibodies and their use in the treatment of cancer, in particular triple negative breast cancer.

A method for treating head and neck tumors is provided, specifically relating to the use of a compound of formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for treating head and neck tumors, wherein the compound of formula (I) produces good efficacy in reducing tumor growth or even eliminating tumors.

The present invention relates to multi-specific T cell engagers and the use thereof. Specifically, the present invention provides the multi-specific T cell engager, comprising a first targeting domain targeting leucine-rich repeat containing protein 15 (LRRC15) molecules highly expressed on the surface of a tumor cell, and further comprising a second targeting domain and / or a third targeting domain bound to the CD molecules of T cell surface. The LRRC15 related multi-specific T cell engagers of the present invention can effectively activate T cells and reduce the tumor stroma impact, and can be used as an effective therapeutic agent for treatment of tumors, especially tumors with a high expression level of LRRC15.